Effectiveness of sacubitril–valsartan in cancer patients with heart failure

AIMS: Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín‐Garcia, Ana, López‐Fernández, Teresa, Mitroi, Cristina, Chaparro‐Muñoz, Marinela, Moliner, Pedro, Martin‐Garcia, Agustin C., Martinez‐Monzonis, Amparo, Castro, Antonio, Lopez‐Sendon, Jose L., Sanchez, Pedro L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160493/
https://www.ncbi.nlm.nih.gov/pubmed/32022485
http://dx.doi.org/10.1002/ehf2.12627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160493/
https://www.ncbi.nlm.nih.gov/pubmed/32022485
http://dx.doi.org/10.1002/ehf2.12627

Ejemplares similares